Physician profile
Kera Thompson
NPI 1659028744
$852.10
in general payments reported to CMS, 2019-2025
23 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $589 · 2024: $147 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $852.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $852.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $177.68 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $94.92 | 2023-2024 | Enhertu, Lynparza |
| Novartis Pharmaceuticals Corporation | $92.73 | 2023-2025 | |
| Genzyme Corporation | $64.24 | 2023 | |
| Janssen Biotech, INC. | $50.52 | 2023 | Darzalex, Tecvayli |
| Tersera Therapeutics LLC | $37.19 | 2023 | Xermelo |
| Eisai INC. | $35.52 | 2023 | |
| Lilly USA, LLC | $30.43 | 2023-2024 | Jaypirca, Verzenio |
| Bayer Healthcare Pharmaceuticals INC. | $22.81 | 2023 | |
| Seagen INC. | $22.07 | 2023 | Padcev |
| Progenics Pharmaceuticals, INC. | $21.80 | 2023 | Pylarify |
| Coherus Oncology, INC. | $20.68 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.37 | 2023 | Alunbrig |
| Genmab U.S., INC. | $19.01 | 2023 | Tivdak |
| Genentech USA, INC. | $18.96 | 2023 | Phesgo, Perjeta |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $17.78 | 2023 | Fotivda |
| Pfizer INC. | $16.44 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $16.00 | 2023 | Libtayo |
| Celgene Corporation | $15.35 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $14.98 | 2025 | Opdivo |
| Amgen INC. | $14.66 | 2023 | Lumakras |
| Rigel Pharmaceuticals, INC. | $14.59 | 2023 | Rezlidhia, Tavalisse |
| Puma Biotechnology, INC. | $14.37 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kera Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.